To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Infliximab Inhibits Activ… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Infliximab Inhibits Activation and Effector Functions of Peripheral Blood T Cells in vitro from Patients with Clinically Active Ulcerative Colitis

Journal article
Authors Rahil Dahlén
Hans Strid
Anna Lundgren
Stefan Isaksson
Sukanya Raghavan
Maria K Magnusson
Magnus Simrén
Henrik Sjövall
Lena Öhman
Published in Scandinavian Journal of Immunology
Volume 78
Issue 3
Pages 275-284
ISSN 0300-9475
Publication year 2013
Published at Institute of Biomedicine, Department of Microbiology and Immunology
Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
Pages 275-284
Language en
Keywords Adult, Aged, Anti-Inflammatory Agents, Non-Steroidal, pharmacology, therapeutic use, Antibodies, Monoclonal, pharmacology, therapeutic use, Apoptosis, drug effects, CD4-Positive T-Lymphocytes, drug effects, immunology, CD8-Positive T-Lymphocytes, drug effects, immunology, Cell Proliferation, drug effects, Colitis, Ulcerative, drug therapy, immunology, metabolism, Female, Forkhead Transcription Factors, metabolism, Granzymes, secretion, Humans, Interferon-gamma, secretion, Interleukin-13, secretion, Interleukin-17, secretion, Interleukin-2 Receptor alpha Subunit, metabolism, Lymphocyte Activation, drug effects, Male, Middle Aged, Tumor Necrosis Factors, secretion, Young Adult
Subject categories Gastroenterology and Hepatology, Immunology in the medical area


Many patients with inflammatory bowel disease (IBD) are undergoing therapy with infliximab, an antibody specific for TNF. However, the exact mechanisms of action of infliximab are not completely understood. The aim of this study was to determine the in vitro effects of infliximab on blood T cells derived from anti-TNF therapy-naive ulcerative colitis (UC) patients with clinically active disease. Peripheral blood mononuclear cells were stimulated polyclonally or by antigen in the presence or absence of infliximab. The T cell phenotype was investigated by flow cytometry, cytokine secretion was determined by ELISA, and cell proliferation was determined by thymidine assay or CFSE dye. Presence of infliximab resulted in reduced expression of CD25 in CD4(+) and CD8(+) T cell populations and inhibited secretion of IFN-, IL-13, IL-17A, TNF as well as granzyme A. Infliximab also suppressed CD4(+) and CD8(+) T cell proliferation. These effects of infliximab were recorded both in T cells activated by polyclonal and antigen-specific stimulation. The effects of infliximab on T cell apoptosis and induction of FOXP3(+)CD4(+) T regulatory cells were ambiguous and depended on the originating cellular source and/or the stimulation mode and strength. In conclusion, infliximab is able to reduce T cell activation as measured by CD25, proliferation and cytokine secretion in vitro from UC patients with clinically active disease. These data suggest that suppression of T cell activity may be important for infliximab-mediated disease remission in patients with UC.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?